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Alzheimer’s disease (AD) is a prevalent disorder and the most common cause of dementia in elderly 
populations. Genetic and environmental factors together play a role in developing late onset 
Alzheimer's disease (LOAD). According to the recent published papers, ACE is one of the candidate 
susceptibility genes for LOAD. In this study, allele and genotype frequencies for rs4291 and rs1799752 
polymorphisms of ACE gene, for 100 Iranian patients, affected with AD and 100 healthy controls were 
compared using Chi-square test. No statistically significant differences were found in genotype and 
allele frequencies of rs4291 and rs1799752 polymorphisms between our LOAD patients and controls. 
The pair-wise haplotype analysis of rs4291 -240 A/T and rs1799752 Alu I/D polymorphisms were also 
performed, but no significant associations were identified.  
 





Alzheimer’s disease (AD) is the most common form of 
dementia in elderly populations (Hardy, 1997). AD is a 
heterogeneous and multifactorial neurodegenerative dis-
order (Iqbal and Grundke-Iqbal, 2000) which is clinically 
characterized by progressive loss of memory and 
cognitive abilities, disorientation to time and place, 
problems with language and changes in personality 
(Rocchi et al., 2003). 
Neuropathological signs of AD are neurofibrillary 
tangles and amyloid plaques in the medial temporal lobe 
structures and cortical areas of the brain (Masters and 
Beyreuther, 2006). 
AD, based upon the age at onset before or after about 
60 years, is categorized into two types called early onset 
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respectively. According to literature, early onset AD is 
inherited as an autosomal dominant trait. However, the 
most Alzheimer’s cases are sporadic with senile form. 
Genetic and environmental factors cooperate with each 
other in developing late onset Alzheimer’s disease 
(LOAD) that constitutes the most population of 
Alzheimer’s patients worldwide (Rocchi et al., 2003). 
Over the last decades, genetic association studies 
have been used to suggest numerous underlying genes 
for Alzheimer’s disease. Mutations in APP, PSEN1 and 
PSEN2 genes have been suggested as a cause of AD in 
the early onset patients (Goate et al., 1991; Sherrington 
et al., 1995; Levy-Lahadet al., 1995). 
Inheritance of APOE ε4 allele has been identified to be 
a risk factor for both early and late onset forms of 
Alzheimer’s disease (Saunders et al., 1993; Farrer et al., 
1997). On the other hand, a few other genes including 
ACE have been considered as candidate susceptibility 
genes for LOAD. 
ACE gene, at locus 17q23, consists of 25 exons, 
encodes angiotensin converting enzyme. This functional 
protein   removes   two   amino   acids  from  the  carboxy  




Table 1. Genetic variations of ACE. 
 
Marker name Map position Genetic location Minor allele 
rs4291 58,907,926 Promoter SNP T 




terminal of angiotensin I and converts it to angiotensin II 
which is an effective vasopressor (OMIM, 106180). ACE 
is expressed in many tissues, including vascular endo-
thelial cells, renal epithelial cells, and testicular Leydig 
cells (Ramaraj et al., 1998). ACE is a pivotal enzyme for 
blood pressure regulation and its level in the blood has 
an association with cardiovascular risk (Breteler, 2000). 
In this study, we analyzed two genetic polymorphisms 
of ACE including rs4291 and rs1799752. These two 
polymorphisms have been reported to have an 
association with LOAD. Their criteria are shown in Table 
1. rs4291 A/T is a promoter single nucleotide poly-
morphism located at -240 bp from the initiation codon of 
the gene. rs1799752 or Alu I/D variation is based on the 
insertion or deletion of a 287 base pair Alu sequence in 
the intron 16 of ACE gene.  
Previous suggestions of the probable association of 
some genetic variations with AD and also their conflicting 
results in different populations encouraged us to investi-
gate the association of LOAD with rs4291 and rs1799752 
allele distributions and also pair-wise haplotype analysis 
of these two polymorphisms through a case-control study 
among Iranian population.  
In this genetic epidemiological study, the frequencies of 
ACE A and T alleles for rs4291, I and D alleles for 
rs1799752 were compared and pair-wise haplotype 
analysis of rs4291 and rs1799752 were also performed in 
independent case and control populations. 
 
 




100 Iranian patients, affected with AD and 100 Iranian normal 
persons, without family history of AD, as control, were studied. The 
age of onset for patients was 74.28±7.7 years, and the cases and 
controls were matched by sex, age, ethnic background, and 
geographic areas. Our patients were collected from the dementia 
outpatient clinic of the Iranian Alzheimer Association (IAA), a 
member of the Alzheimer’s Disease International (ADI) and also 
from a few nursing homes in Tehran, Iran. All patients met standard 
diagnostic criteria for AD. Cases had been corroborated to have 
Alzheimer’s disease according to neurological and neuro-
psychological testing, including the Mini-Mental State Examination 
[MMSE] or Folstein test (Folstein et al., 1975) accomplished by 
neurologists in IAA. Our controls were 100 non-demented elderly 
individuals. None of them had clinical history of neuropathological 
or psychiatric disorders in their families. All the patients or their 
legal guardians and all the controls, signed informed consent 
document, and the study was approved by the Ethics Committee of 
the Hospital before it was commenced. 
Genotyping 
 
A blood sample was collected from each patient and control. In the 
next step, genomic DNA was extracted from white blood cells using 
a salt-out procedure (Miller et al., 1988). All cases and control 
samples were evaluated for rs4291 and rs1799752 polymorphisms. 
Genotypes for rs4291 were also determined by an allele specific 
PCR protocol and 186 base pair products were observed by 
electrophoresis assay. Forward and reverse specific primers for 
allele A were: 5’-ACTGCCGGGTCCCCATCTTGA and 5’-
GCTTCCTCCTCCGCTCCAGAG. Allele T specific primers were 5’-
ACTGCCGGGTCCCCATCTCCT and 5’-GCTTCCTCCTCCGCT-
CCAGAG. Since SNP rs4291 is located in a GC rich region, betaine 
(1 mM) was used to increase amplification. The accuracy of 186 
base pair PCR products for some samples was checked by 
bidirectional sequencing. For determination of genotype of the 
rs1799752 polymorphism, two PCR series were performed. In the 
first reaction, primers that flank I/D polymorphism were used to 
amplify DNA from each subject (5´- CTGGAGACCACT 
CCCATCCTTTCT and 5´-GATGTGGCCATCACATTCGTCAGA). 
The resulting PCR products included 490 base pair and 190 base 
pair bands for I and D alleles, respectively. Due to the fact that this 
reaction frequently fails to detect the insertion allele, a second PCR 
reaction was performed which specifically amplifies the allele 
containing the insertion primers (5´- CTGGGATTA 
CAGGCGTGATACA and 5´-TTGATG AGTTCCACGTATTTCG). 
The resulting PCR product was a 259 base-pair fragment. The data 






All statistical calculations were performed using Statistical Package 
for Social Science, version 17.0 (SPSS, Chicago, USA). Genotype 
and allele frequencies for rs4291 and rs1799752 were compared 
between case and control groups by using Chi-square analysis. 
Whenever appropriate, the observed number of each genotype was 
compared with the expected for a population in the Hardy-Weinberg 
equilibrium by using a goodness of fit x
2
 test. Differences were 
considered significant if the p value was less than 0.05. 
 
 
RESULTS AND DISCUSSION 
 
The main finding of our study was the lack of association 
between ACE rs4291 and also rs1799752 polymorphisms 
with the risk of developing AD in our Iranian group of 
LOAD patients. According to the results shown in Tables 
2 and 3 and Figures 1 and 2, no statistically significant 
differences were found in genotype and allele fre-
quencies of rs4291 and rs1799752 polymorphisms bet-
ween our LOAD patients and controls.  
The pair-wise haplotype analysis of rs4291 -240 A/T 
and     rs1799752    Alu I/D   polymorphisms    were   also   




Table 2. Genotyping.   
 
Variable 
Genotype  Allele 
AA AT TT  A T 
Cases (n = 100) 31 50 19  112 88 




 = 1.23, p = 0.5; alleles:  x
2




Table 3. Genotyping.  
 
Variable 
Genotype  Allele 
DD ID II  I D 
Cases (n = 100) 32 49 19  87 113 




 = 0.741, p = 0.6; alleles: x
2




analyzed and the results are shown in Table 4. No 
significant association between various haplotypes of 
these two sites and LOAD was observed (P = 0.19). 
The study of rs1799752 or I/D polymorphism has been 
of interest in genetic research on LOAD. Such study has 
been performed among different populations around the 
world and conflicting results have been obtained. 
Literature review revealed the association between ACE 
I/D polymorphism and incidence of LOAD in 14 studies 
(Alvarez et al., 1999; Cheng et al., 2002; Crawford et al., 
2000; Helbecque et al., 2009; Hu et al., 1999; Kehoe et 
al., 1999, 2003; Kölsch et al., 2005; Mattila et al., 2000; 
Narain et al., 2000; Ning et al., 2010; Richard et al., 2001; 
Wang et al. 2006; Wang et al., 2006) which shows 
positive association. However, there was no association 
between this polymorphism and LOAD in 20 studies 
(Buss et al., 2002; Camelo et al., 2004; Carbonell et al., 
2003; Chapman et al., 1998; Cousin et al., 2009; 
Keikhaee et al., 2006; Lehmann et al., 2005; Lendon et 
al., 2002; Meng et al., 2006; Monastero et al., 2002; 
Myllykangas et al., 2000; Nacmias et al., 2007; Palumbo 
et al., 1999; Panza, 2002; Perry et al., 2001; Scacchi et 
al., 1998; Seripa et al., 2003; Wakutani et al., 2002; Wehr 
et al., 2006; Zuliani et al., 2001) showing negative 
association. 
According to several biochemical researches, N-
terminal catalytic domain of ACE has the ability of 
degrading of amyloid-β (Aβ) peptide in vitro. It has been 
observed that ACE inhibitors can block this effect of the 
enzyme. It seems that the low level of ACE might result in 
the increase of the accumulation of A peptide as a 
hallmark of LOAD (Hemming and Selkoe, 2005; Sun et 
al., 2008). On the other hand, rs1799752 was found to be 
strongly associated with the level of circulating ACE 
(Rigat et al., 1990). As a result, this insertion deletion 
polymorphism might have a link with incidence of LOAD. 
However, in vivo studies in mice (Eckman et al., 2006; 









Figure 1. Electrophoresis assay for PCR products by allele 




(Lendon  et al., 2002; Minerset al., 2009) have shown no 
change in brain A peptide levels according to ACE 
availability. This finding disagrees with the association of 
insertion/deletion polymorphism rs1799752 with A 
peptide level in brain.  
Our results show that there was no statistical significant 
association between rs1799752 and LOAD among 
Iranian population. Our results confirm the previous study 
on this polymorphism in an independent Iranian 
population of LOAD cases (Keikhahee et al., 2006). It 
appears that the whole genetic and biochemical findings 
about rs1799752 insertion/deletion polymorphism do not 
completely support each other.  
According to one study, rs4291 A/T influences the 
levels of toxic A peptide in the cerebrospinal fluid (CSF) 
(Kehoe et al., 2003). Moreover, rs4291 was reported to 
be associated with plasma ACE levels (McKenzie et al., 
2005). 
Kehoe et al. (2003) showed that this SNP has the 
strongest link to incidence of AD amongst ACE single 
nucleotide polymorphisms in a large study on Swedish, 
Scottish and English independent populations. There are  











Table 4. Pair-wise haplotype analysis for rs4291 and 
rs1799752 polymorphisms; x
2
= 6.15, p = 0.19. 
   
Haplotype Patient (100) Control (100) 
-240 A/T – I/D   
A-I 48 51 
A-D 32 43 
T-I 7 2 
T-D 49 54 
Undefined 32 25 
 
A-I haplotypes were detected from AAII, AAID and ATII 
genotypes; A-D haplotypes from AADD, AAID and ATDD 
genotypes; T-I haplotypes from TTII, TTID and ATII genotypes; 
and T-D haplotypes from TTDD, TTID and ATDD genotypes. 





six other studies, from various populations, reporting an 
association between LOAD and rs4291 genotype or 
regarding haplotype structures (Kehoe et al., 1999, 2003; 
Wang et al., 2006; Edwards et al., 2008; Helbecque et 
al., 2009; Ghebranious et al., 2010). However, the results 
of three other separate studies were not consistent with 
their results. They found no association between LOAD 
and rs4291 (Meng et al., 2006; Bruandet et al., 2008; 
Cousin et al., 2009). According to these results, rs4291 
were not associated with LOAD in French Caucasian 
population and also among Israeli Arab community. 
We could not detect any statistically significant 
associations between rs4291 A/T and LOAD among our 
cases. Our patients were from different regions of Iran 
and we completely matched our cases and controls in 
terms of age and gender. We also found no haplotypic 
association regarding rs4291 and rs1799752 among our 
cases (Table 4). 
There were different reasons  which  could  explain  the 
discrepancies in the results observed in various studies. 
The negative results may be explained by the fact that 
the gene(s) responsible for the disease are probably 
different in various populations and that the epistatic 
gene-gene interactions or specific multi-loci haplotype 
may be involved in determining the association. 
A recent meta-analytical study on three ACE poly-
morphisms including rs4291 among 10 Caucasian case-
control populations has been performed for finding their 
association with LOAD. According to their statistical 
results, rs4291 was not associated with LOAD in those 
Caucasian populations. This research group also found 
no haplotypic association in their complete dataset 
(Belbin et al., 2011). 
They suggested that ACE variants have modest effect 
sizes, which are likely part of a complex interaction 
between genetic, phenotypic and pharmacological effects 






Our conclusion is in agreement with the negative 
association between AD and ACE polymorphism.   The 
failure to determine an association between AD and ACE 
polymorphism in our study may be due to the small size 
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